Phio Pharmaceuticals Corp.
PHIO
$2.40
-$0.08-3.23%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 236.36% | -2.18% | -64.38% | -- | -100.52% |
| Gross Profit | -236.36% | 2.18% | 64.38% | -- | 100.52% |
| SG&A Expenses | -7.07% | -10.05% | -2.27% | -9.97% | -27.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.26% | -5.58% | -42.72% | -24.85% | -38.67% |
| Operating Income | 15.26% | 5.58% | 42.72% | 24.85% | 38.67% |
| Income Before Tax | 17.87% | 14.20% | 45.18% | 27.58% | 40.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.87% | 14.20% | 45.18% | 27.58% | 40.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.87% | 14.20% | 45.18% | 27.58% | 40.20% |
| EBIT | 15.26% | 5.58% | 42.72% | 24.85% | 38.67% |
| EBITDA | 15.24% | 5.05% | 42.41% | 24.45% | 38.43% |
| EPS Basic | 12.67% | 74.77% | 84.99% | 72.74% | 98.34% |
| Normalized Basic EPS | 12.66% | 72.98% | 84.99% | 72.74% | 98.34% |
| EPS Diluted | 12.67% | 74.77% | 84.99% | 72.73% | 98.34% |
| Normalized Diluted EPS | 12.66% | 72.98% | 84.99% | 72.74% | 98.34% |
| Average Basic Shares Outstanding | -5.96% | 240.07% | 265.18% | 165.59% | 3,509.22% |
| Average Diluted Shares Outstanding | -5.96% | 240.07% | 265.18% | 165.59% | 3,509.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |